{"id":952870,"date":"2026-04-20T09:03:18","date_gmt":"2026-04-20T13:03:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\/"},"modified":"2026-04-20T09:03:18","modified_gmt":"2026-04-20T13:03:18","slug":"abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\/","title":{"rendered":"AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call<\/b><\/p>\n<p>VANCOUVER, British Columbia&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.abcellera.com&amp;esheet=54517506&amp;newsitemid=20260420968823&amp;lan=en-US&amp;anchor=AbCellera&amp;index=1&amp;md5=09f98b2060fcd7a142222423df2f40b8\">AbCellera<\/a> (Nasdaq: ABCL) today announced that it will disclose interim results from the Phase 1 portion of its study of ABCL635, including observed safety profile, pharmacokinetic, and pharmacodynamic target engagement data, during its first quarter 2026 earnings call on Monday, May 11, 2026.<\/p>\n<p>\nABCL635 is a potential first-in-class antibody therapeutic targeting the neurokinin 3 receptor (NK3R) for the non-hormonal treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. It is currently being evaluated in a Phase 1\/2 study, and the results of the ongoing multicenter, randomized, double-blind, placebo-controlled Phase 2 portion in postmenopausal women with moderate-to-severe VMS are anticipated in Q3 2026.<\/p>\n<p>\nAs <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.abcellera.com%2Fnews%2Fnews-releases%2F2026%2FAbCellera-to-Report-First-Quarter-2026-Financial-Results-on-May-11-2026%2Fdefault.aspx&amp;esheet=54517506&amp;newsitemid=20260420968823&amp;lan=en-US&amp;anchor=previously+announced&amp;index=2&amp;md5=865d00c779cd93f8d9c5f7369d7d22ad\">previously announced<\/a>, AbCellera will host its first quarter 2026 earnings call on Monday, May 11, 2026 at 2:00 p.m. PT (5:00 p.m. ET). A live audio webcast of the earnings conference may be accessed through a link that will be posted on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.abcellera.com%2Foverview%2Fdefault.aspx&amp;esheet=54517506&amp;newsitemid=20260420968823&amp;lan=en-US&amp;anchor=AbCellera%26%238217%3Bs+Investor+Relations+website&amp;index=3&amp;md5=97062ae2b3db8a527362cf020791369d\">AbCellera\u2019s Investor Relations website<\/a>. A replay will be available through the same link following the conference call.<\/p>\n<p><b>About ABCL635<\/b><\/p>\n<p>\nABCL635 is a potential first-in-class antibody medicine for the non-hormonal treatment of moderate-to-severe VMS, commonly known as hot flashes, associated with menopause. ABCL635 specifically targets NK3R, a clinically validated G protein-coupled receptor (GPCR) expressed on kisspeptin, neurokinin B, and dynorphin (KNDy) neurons in the infundibular nucleus of the hypothalamus. ABCL635 is the first program from AbCellera\u2019s GPCR and ion channel platform to advance into the pipeline, entering the clinic in July 2025. Additional details are available at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fclinicaltrials.gov&amp;esheet=54517506&amp;newsitemid=20260420968823&amp;lan=en-US&amp;anchor=ClinicalTrials.gov&amp;index=4&amp;md5=bf7396ca3b48c096a27ab3b91039ae56\">ClinicalTrials.gov<\/a>.<\/p>\n<p><b>About AbCellera Biologics Inc.<\/b><\/p>\n<p><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.abcellera.com&amp;esheet=54517506&amp;newsitemid=20260420968823&amp;lan=en-US&amp;anchor=AbCellera&amp;index=5&amp;md5=8de0b20e3260e5596f6fc27cfd497aad\">AbCellera<\/a> (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women\u2019s health, immunology, oncology, and more. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.abcellera.com&amp;esheet=54517506&amp;newsitemid=20260420968823&amp;lan=en-US&amp;anchor=www.abcellera.com&amp;index=6&amp;md5=71d777c727a5e9f8c17c1161d4afb4c3\">www.abcellera.com<\/a>.<\/p>\n<p><b>AbCellera Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management\u2019s current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.<\/p>\n<p>\nIn some cases, you can identify forward-looking statements by the words \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201congoing\u201d or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors are described under \u201cRisk Factors,\u201d \u201cManagement&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,\u201d and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260420968823r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260420968823\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260420968823\/en\/<\/a><\/span><\/p>\n<p><b>Inquiries<\/p>\n<p><\/b>Media: Tiffany Chiu; <a rel=\"nofollow\" href=\"mailto:media@abcellera.com\">media@abcellera.com<\/a>, +1(236)521-6774<br \/>\n<br \/>Partnering: Murray McCutcheon, Ph.D.; <a rel=\"nofollow\" href=\"mailto:partnering@abcellera.com\">partnering@abcellera.com<\/a>, +1(604)559-9005<br \/>\n<br \/>Investor Relations: Peter Ahn; <a rel=\"nofollow\" href=\"mailto:ir@abcellera.com\">ir@abcellera.com<\/a>, +1(778)729-9116<\/p>\n<p><b>KEYWORDS:<\/b> United States North America Canada<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology General Health Health Pharmaceutical Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260420968823\/en\/705128\/3\/AbCellera_Full_Colour_RGB_1.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call VANCOUVER, British Columbia&#8211;(BUSINESS WIRE)&#8211;AbCellera (Nasdaq: ABCL) today announced that it will disclose interim results from the Phase 1 portion of its study of ABCL635, including observed safety profile, pharmacokinetic, and pharmacodynamic target engagement data, during its first quarter 2026 earnings call on Monday, May 11, 2026. ABCL635 is a potential first-in-class antibody therapeutic targeting the neurokinin 3 receptor (NK3R) for the non-hormonal treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. It is currently being evaluated in a Phase 1\/2 study, and the results of the ongoing multicenter, randomized, double-blind, placebo-controlled Phase 2 portion in postmenopausal women with moderate-to-severe VMS are anticipated in Q3 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-952870","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call VANCOUVER, British Columbia&#8211;(BUSINESS WIRE)&#8211;AbCellera (Nasdaq: ABCL) today announced that it will disclose interim results from the Phase 1 portion of its study of ABCL635, including observed safety profile, pharmacokinetic, and pharmacodynamic target engagement data, during its first quarter 2026 earnings call on Monday, May 11, 2026. ABCL635 is a potential first-in-class antibody therapeutic targeting the neurokinin 3 receptor (NK3R) for the non-hormonal treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. It is currently being evaluated in a Phase 1\/2 study, and the results of the ongoing multicenter, randomized, double-blind, placebo-controlled Phase 2 portion in postmenopausal women with moderate-to-severe VMS are anticipated in Q3 &hellip; Continue reading &quot;AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-20T13:03:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260420968823r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call\",\"datePublished\":\"2026-04-20T13:03:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\\\/\"},\"wordCount\":663,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260420968823r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\\\/\",\"name\":\"AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260420968823r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-04-20T13:03:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260420968823r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260420968823r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\/","og_locale":"en_US","og_type":"article","og_title":"AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call - Market Newsdesk","og_description":"AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call VANCOUVER, British Columbia&#8211;(BUSINESS WIRE)&#8211;AbCellera (Nasdaq: ABCL) today announced that it will disclose interim results from the Phase 1 portion of its study of ABCL635, including observed safety profile, pharmacokinetic, and pharmacodynamic target engagement data, during its first quarter 2026 earnings call on Monday, May 11, 2026. ABCL635 is a potential first-in-class antibody therapeutic targeting the neurokinin 3 receptor (NK3R) for the non-hormonal treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. It is currently being evaluated in a Phase 1\/2 study, and the results of the ongoing multicenter, randomized, double-blind, placebo-controlled Phase 2 portion in postmenopausal women with moderate-to-severe VMS are anticipated in Q3 &hellip; Continue reading \"AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-20T13:03:18+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260420968823r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call","datePublished":"2026-04-20T13:03:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\/"},"wordCount":663,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260420968823r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\/","name":"AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260420968823r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-04-20T13:03:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260420968823r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260420968823r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-to-highlight-phase-1-clinical-data-for-abcl635-during-upcoming-first-quarter-2026-earnings-call\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952870","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=952870"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952870\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=952870"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=952870"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=952870"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}